NCT05679895

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed/Refractory (R/R) T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: OneChain Immunotherapeutics · Industry
• Sex: All
• Age: 2 Years
• Healthy volunteers: Not accepted

Summary

First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)

Conditions

• T-cell Acute Lymphoblastic Leukemia
• Lymphoblastic T-Cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	CD1a-CAR T	Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach

Timeline

• Start date: 2023-01-31
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2023-01-11
• Last updated: 2026-03-11

Locations

2 sites across 1 country: Spain